AstraZeneca / Alexion: The Next Major M&A Is Here

 

• AstraZeneca has announced its acquiring Alexion at a fairly substantial 45% premium. It's a mixed stock - cash offer.
• The synergies will cover most of the ~$900 million in annual dividend / interest costs with significant growth potential.
• AstraZeneca is working to position itself for substantial long-term growth for shareholders.
• I do much more than just articles at The Energy Forum: Members get access to model portfolios, regular updates, a chat room, and more

AstraZeneca recently announced plans to acquire Alexion, a company we've discussed before here. The massive $39 billion acquisition is a 45% premium to the company's Friday closing price. It's the latest in a spate of major acquisitions like Bristol-Myers Squibb acquiring Celgene, discussed here, 

 Ver:

BMS to acquire Celgene for $74 billion in biggest-ever pharma deal

and AbbVie acquiring Allergan.

Ver:

ABBVIE & ALLERGAN nuevo merger...

 Más